-
-
A selective estrogen receptor modulator (SERM), also known as an estrogen agonist/antagonist, has been approved by the FDA for the treatment of dyspareunia (painful intercourse) in postmenopausal women. Ospemifene is manufactured by Penn Pharmaceuticals Services Ltd. and marketed by Shionogi Inc. as Osphena.
-
The authors concluded that in patients with AF, decreasing GFR was associated with a higher risk of cardiovascular events and bleeding. Apixaban as compared to warfarin reduced these risks regardless of renal function, with the greatest benefit seen in reducing major bleeding in those with impaired renal function.
-
Adults with private health care insurance in the United States have suboptimal testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV). Clearly, increased awareness is needed regarding HBV and HCV infections, epidemiology, risk, and screening.
-
Among deployed U.S. service members who died of combat or unintentional injuries and received autopsies, the prevalence of atherosclerosis varied by age and cardiovascular risk factors.
-
A prospective study on Epstein-Barr virus seronegative college freshmen found that primary infection was symptomatic in 89% of cases. Kissing was the primary risk factor for infection, and blood viral load, CD8+ lymphocytosis, and IL-6 levels correlated with disease severity.
-
A More Effective Regimen for H. pylori Eradication; Uric Acid: How Much of a Bad Guy?; The Word GPR40 Modulator May Soon be Entering Our Vocabulary
-
Remember that scene in Doc Martin when he travels to London for a conference, and while his lady awaits his affection in a tiny negligee, he methodically strips the bed looking for bed bugs? How many of us make that a habit now when traveling?
-
Exercise, both aerobic as well as stretching and strengthening, improves motor function and gait in patients with Parkinsons disease.
-
A second ezetimbe/statin combination has been approved by the FDA for the treatment of hyperlipidemia. Ezetimibe is now combined with atorvastatin and is marketed by Merck & Co. as Liptruzet.
